Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings From the Initial Screening Round of a Randomized Trial
G. L. Andriole(Washington University in St. Louis), E. David Crawford(University of California San Diego), David L. Levin(University of California San Diego), Philip C. Prorok(National Cancer Institute), John K. Gohagan(National Institutes of Health), Timothy R. Church(University of Minnesota), David Chia(University of California, Los Angeles), Edward P. Gelmann(University of Arizona), Paul F. Pinsky(National Cancer Institute), Lawrence R. Ragard(Westat (United States)), Jonathan D. Clapp(National Institutes of Health), Robert L. Grubb, Douglas J. Reding(Ascension), Grant Izmirlian(National Institutes of Health), Barnett S. Kramer(University of Pittsburgh)
Cited by 245
Related Papers
Reducing Mortality from Colorectal Cancer by Screening for Fecal Occult Blood
|New England Journal of Medicine|1993|3.3k
Mortality Results from a Randomized Prostate-Cancer Screening Trial
|New England Journal of Medicine|2009|2.9k
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
|JNCI Journal of the National Cancer Institute|2008|1.7k
The Effect of Fecal Occult-Blood Screening on the Incidence of Colorectal Cancer
|New England Journal of Medicine|2000|1.4k
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24
|Nature Genetics|2007|1.1k